NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis $5.21 +0.18 (+3.58%) Closing price 04:00 PM EasternExtended Trading$5.18 -0.04 (-0.67%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About PolyPid Stock (NASDAQ:PYPD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PolyPid alerts:Sign Up Key Stats Today's Range$5.06▼$5.3050-Day Range$3.74▼$5.3952-Week Range$3.06▼$5.73Volume66,361 shsAverage Volume125,890 shsMarket Capitalization$99.42 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingModerate Buy Company Overview PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing locally administered therapies designed to provide controlled and sustained drug delivery at treatment sites. The company’s proprietary PLEX polymer-lipid encapsulation matrix is intended to release therapeutic agents over an extended period, with the goal of improving treatment effectiveness and reducing the need for repeated systemic dosing. PolyPid’s lead product candidate is D-PLEX100, an investigational formulation containing doxycycline that is designed for administration at surgical sites. The product has been developed primarily for the prevention of surgical-site infections, including infections associated with colorectal and other abdominal procedures. D-PLEX100 has been evaluated in clinical studies, including late-stage trials, although its development and regulatory status may change as the company assesses clinical and business priorities. Founded in 2005 and headquartered in Israel, PolyPid has focused its research and development activities on applying its drug-delivery platform to surgical care and other localized treatment settings. The company has conducted clinical development and business activities involving international markets, including the United States, where its securities have traded under the symbol PYPD. PolyPid’s pipeline and corporate activities have centered on advancing its proprietary delivery technology and evaluating potential partnerships or applications for its products.AI Generated. May Contain Errors. Read More PolyPid Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScorePYPD MarketRank™: PolyPid scored higher than 54% of companies evaluated by MarketBeat, and ranked 448th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingPolyPid has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPolyPid has a consensus price target of $11.33, representing about 118.2% upside from its current price of $5.20.Amount of Analyst CoveragePolyPid has only been the subject of 2 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PolyPid are expected to decrease in the coming year, from ($0.92) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolyPid has a P/B Ratio of 7.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PolyPid's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.36% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 15.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. News and Social Media1.6 / 5News SentimentN/A News SentimentPolyPid has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for PolyPid this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PYPD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PYPD Stock News HeadlinesPolyPid Announces Participation in Upcoming Fall Investor ConferencesSeptember 15 at 8:30 AM | globenewswire.comPolyPid (PYPD) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved.September 18 at 1:00 AM | Banyan Hill Publishing (Ad)PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...August 12, 2026 | finance.yahoo.comPolyPid Ltd. (PYPD) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | seekingalpha.comPolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsAugust 12, 2026 | globenewswire.comPolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)July 31, 2026 | markets.businessinsider.comPolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026July 30, 2026 | quiverquant.comQSee More Headlines PYPD Stock Analysis - Frequently Asked Questions How have PYPD shares performed this year? PolyPid's stock was trading at $4.34 at the beginning of the year. Since then, PYPD shares have increased by 19.7% and is now trading at $5.1950. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.03. Read the conference call transcript. When did PolyPid's stock split? Shares of PolyPid reverse split before market open on Thursday, September 21st 2023.The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PolyPid IPO? PolyPid (PYPD) raised $60 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,750,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? Top institutional investors of PolyPid include AIGH Capital Management LLC (7.89%), ADAR1 Capital Management LLC (0.54%), Symmetry Peak Management LLC (0.53%) and J. Goldman & Co LP (0.52%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU). Company Calendar Last Earnings8/12/2026Today9/18/2026Lytham Partners Fall 2026 Investor Conference9/29/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PYPD's financial health is in the Green zone, according to TradeSmith. PYPD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PYPD CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees75Year Founded2008Price Target and Rating Average Price Target for PolyPid$11.33 High Price Target$13.00 Low Price Target$9.00 Potential Upside/Downside+117.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-311.08% Return on Assets-150.83% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book7.55Miscellaneous Outstanding Shares19,083,000Free Float14,369,000Market Cap$99.42 million OptionableNo Data Beta1.41 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PYPD) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
